Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer m...

Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models  Nature

Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocel...

Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma  The ASCO Post

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Co...

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Combat Multi-Pathway Drug Resistance in Hepatocellular Carcinoma  ACS Publications

First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib mono...

First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials  Frontiers

From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma ...

From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma  ASCO Daily News

Frontline Sorafenib Shows Promising Outcomes in Metastatic Uveal Melanoma - CancerNetwork

Frontline Sorafenib Shows Promising Outcomes in Metastatic Uveal Melanoma  CancerNetwork

LEVIATHAN Study Results: Lenvatinib vs Sorafenib as 2L Treatment for Hepatocellular Carcinoma - O...

LEVIATHAN Study Results: Lenvatinib vs Sorafenib as 2L Treatment for Hepatocellular Carcinoma  Oncodaily

Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liv...

Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer  Nature

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Co...

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Combat Multi-Pathway Drug Resistance in Hepatocellular Carcinoma  ACS Publications

The cost effectiveness of toripalimab plus bevacizumab versus sorafenib for the first-line treatm...

The cost effectiveness of toripalimab plus bevacizumab versus sorafenib for the first-line treatment of advanced hepatocellular carcinoma in China  Frontiers

Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial -...

Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial  Nature

Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immun...

Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma  Nature

MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocel...

MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocellular carcinoma and colorectal cancer in vitro  Nature

LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression ...

LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression through modulation of MAPK signaling and apoptosis  Nature

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in he...

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma  Nature

ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carci...

ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma  Nature

D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma ...

D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma  Nature

Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resi...

Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway  Nature

Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular c...

Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular carcinoma  Nature

Immune system development-related signature predicts prognosis and sorafenib-treatment resistance...

Immune system development-related signature predicts prognosis and sorafenib-treatment resistance of hepatocellular carcinoma by intergrating machine learning and single-cell analyses  Nature

Overcoming the sorafenib resistance mechanism in FLT3-mutated acute myeloid leukemia: molecular b...

Overcoming the sorafenib resistance mechanism in FLT3-mutated acute myeloid leukemia: molecular basis and new targets  Frontiers

Final Results of CARES-310 Study: Camrelizumab + Rivoceranib vs Sorafenib in Unresectable HCC - O...

Final Results of CARES-310 Study: Camrelizumab + Rivoceranib vs Sorafenib in Unresectable HCC  Oncodaily

Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellula...

Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellular carcinoma through modulating METTL9-SLC7A11 axis  Nature

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable...

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial  The Lancet

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer - 2 Minu...

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer  2 Minute Medicine

Inhibition of Wnt/β-catenin increases anti-tumor activity by synergizing with sorafenib in hepato...

Inhibition of Wnt/β-catenin increases anti-tumor activity by synergizing with sorafenib in hepatocellular carcinoma  Nature

Complete Radiological Response to Sorafenib in Aggressive Intra-Abdominal Desmoid Tumor A Case Re...

Complete Radiological Response to Sorafenib in Aggressive Intra-Abdominal Desmoid Tumor A Case Report  SCIRP Open Access

Paris court invalidates crucial claim of Bayer’s sorafenib patent - JUVE Patent

Paris court invalidates crucial claim of Bayer’s sorafenib patent  JUVE Patent

Cigarette compound exposure drives sorafenib resistance in hepatocellular carcinoma - News-Medical

Cigarette compound exposure drives sorafenib resistance in hepatocellular carcinoma  News-Medical

FDA Accepts NDA for Rivoceranib and Camrelizumab in 1L Unresectable HCC - CancerNetwork

FDA Accepts NDA for Rivoceranib and Camrelizumab in 1L Unresectable HCC  CancerNetwork

Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatm...

Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China  Frontiers

Frontline Nivolumab/Ipilimumab Delivers Long-Term Efficacy in Unresectable HCC - OncLive

Frontline Nivolumab/Ipilimumab Delivers Long-Term Efficacy in Unresectable HCC  OncLive

Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatm...

Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China  Frontiers

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocell...

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial  The Lancet

Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma - The ...

Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma  The ASCO Post

Analyzing Nivolumab and Ipilimumab as HCC Therapy - Targeted Oncology

Analyzing Nivolumab and Ipilimumab as HCC Therapy  Targeted Oncology

Oleanolic acid restores drug sensitivity in sorafenib-resistant hepatocellular carcinoma: evidenc...

Oleanolic acid restores drug sensitivity in sorafenib-resistant hepatocellular carcinoma: evidence from in vitro and in vivo studies  EurekAlert!

Sorafenib-to-regorafenib sequence-induced atherosclerotic cardiovascular disease: a novel case re...

Sorafenib-to-regorafenib sequence-induced atherosclerotic cardiovascular disease: a novel case report  Frontiers

Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC - ScienceDire...

Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC  ScienceDirect.com

NCOA5 induces sorafenib resistance in hepatocellular carcinoma by inhibiting ferroptosis - Nature

NCOA5 induces sorafenib resistance in hepatocellular carcinoma by inhibiting ferroptosis  Nature

CheckMate 9DW at ASCO GI 2026: Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line...

CheckMate 9DW at ASCO GI 2026: Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma  Oncodaily

Impact of First-Line Treatment on HCC Outcomes - Medscape

Impact of First-Line Treatment on HCC Outcomes  Medscape

NOX1 inhibition sensitizes HCC cells to sorafenib and radiotherapy by modulating ROS-mediated pro...

NOX1 inhibition sensitizes HCC cells to sorafenib and radiotherapy by modulating ROS-mediated programmed cell death  Nature

Application of Helmholtz Coils and superparamagnetic nanocarrier in localized inhibition of cance...

Application of Helmholtz Coils and superparamagnetic nanocarrier in localized inhibition of cancer cell migration and invasion  ScienceDirect.com

Medicine International - Spandidos Publications

Medicine International  Spandidos Publications

Clinical breakthrough: Five-year survival in patients with unresectable hepatocellular carcinoma ...

Clinical breakthrough: Five-year survival in patients with unresectable hepatocellular carcinoma sets an unprecedented milestone poised to reshape clinical practice  EurekAlert!

Combination Therapy Improves Survival in Liver Cancer - European Medical Journal

Combination Therapy Improves Survival in Liver Cancer  European Medical Journal

Sameer Rastogi Shared Early Results from SORASTOP Trial on Discontinuing Sorafenib in Desmoid Tum...

Sameer Rastogi Shared Early Results from SORASTOP Trial on Discontinuing Sorafenib in Desmoid Tumors  Oncodaily

Nivolumab/Ipilimumab Maintains OS, ORR Benefits in Chinese Patients With Unresectable HCC - OncLive

Nivolumab/Ipilimumab Maintains OS, ORR Benefits in Chinese Patients With Unresectable HCC  OncLive

Targeting GPX4 to Overcome Sorafenib Resistance of Human Hepatocellular Carcinoma by Inducing Fer...

Targeting GPX4 to Overcome Sorafenib Resistance of Human Hepatocellular Carcinoma by Inducing Ferroptosis  Wiley Online Library

APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC - Oncodaily

APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC  Oncodaily

Autophagy modulation attenuates sorafenib resistance in HCC induced in rats - Nature

Autophagy modulation attenuates sorafenib resistance in HCC induced in rats  Nature

Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma i...

Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy  Nature

CSF3R-AS promotes hepatocellular carcinoma progression and sorafenib resistance through the CSF3R...

CSF3R-AS promotes hepatocellular carcinoma progression and sorafenib resistance through the CSF3R/JAK2/STAT3 positive feedback loop  Nature

Arndt Vogel Highlights HEPATORCH Trial Results Comparing Toripalimab Plus Bevacizumab with Sorafe...

Arndt Vogel Highlights HEPATORCH Trial Results Comparing Toripalimab Plus Bevacizumab with Sorafenib in Advanced HCC  Oncodaily

Sorafenib for Advanced and Refractory Desmoid Tumors - The New England Journal of Medicine

Sorafenib for Advanced and Refractory Desmoid Tumors  The New England Journal of Medicine

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors - Nature

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors  Nature

Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 ex...

Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 expression  Nature

Mechanism of sorafenib resistance associated with ferroptosis in HCC - Frontiers

Mechanism of sorafenib resistance associated with ferroptosis in HCC  Frontiers

New knowledge of the mechanisms of sorafenib resistance in liver cancer - Nature

New knowledge of the mechanisms of sorafenib resistance in liver cancer  Nature

GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition o...

GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis  Nature

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-...

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma  Nature

CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1 - Nature

CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1  Nature

Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment - Nature

Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment  Nature

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo s...

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling  Nature

3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by dec...

3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness  Nature

Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneo...

Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors  Frontiers

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular ...

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial  The Lancet

Comparison of efficacy and safety of adjuvant therapies versus sorafenib in hepatocellular carcin...

Comparison of efficacy and safety of adjuvant therapies versus sorafenib in hepatocellular carcinoma: a systematic review and network meta-analysis  Frontiers

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeosta...

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma  Nature

Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations an...

Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations and pharmacokinetic studies  Nature

Sorafenib inhibits ossification of the posterior longitudinal ligament by blocking LOXL2-mediated...

Sorafenib inhibits ossification of the posterior longitudinal ligament by blocking LOXL2-mediated vascularization  Nature

RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC ...

RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC signaling via the IRE1α–XBP1s pathway  Nature

TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiqu...

TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC  Nature

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RES...

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial  The Lancet

Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after so...

Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure  Nature

Formulation development, characterization, and evaluation of sorafenib-loaded PLGA–chitosan nanop...

Formulation development, characterization, and evaluation of sorafenib-loaded PLGA–chitosan nanoparticles  Frontiers

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellu...

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study  The Lancet

Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoemboli...

Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma  Nature

Decoding Drug Interactions: Character and Degree of Pharmacokinetic In | DDDT - Dove Medical Press

Decoding Drug Interactions: Character and Degree of Pharmacokinetic In | DDDT  Dove Medical Press

First-Line Immunotherapy Combo Boosts Survival in Unresectable Liver Cancer - MedPage Today

First-Line Immunotherapy Combo Boosts Survival in Unresectable Liver Cancer  MedPage Today

MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferro...

MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferroptosis induction  Nature

TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating...

TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways  Nature

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312...

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study  The Lancet

NRG/RTOG 1112: Radiotherapy Added to Sorafenib Improves Survival in Advanced Hepatocellular Carci...

NRG/RTOG 1112: Radiotherapy Added to Sorafenib Improves Survival in Advanced Hepatocellular Carcinoma  The ASCO Post

Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil-Mediated Lung Metastasis in Hepa...

Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil-Mediated Lung Metastasis in Hepatocellular Carcinoma  Wiley

Combination Therapies Outperform Sorafenib in Hepatocellular Carcinoma - Targeted Oncology

Combination Therapies Outperform Sorafenib in Hepatocellular Carcinoma  Targeted Oncology

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glut...

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase  Nature

Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and acti...

Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition  PNAS

A comprehensive review of the relationship between autophagy and sorafenib-resistance in hepatoce...

A comprehensive review of the relationship between autophagy and sorafenib-resistance in hepatocellular carcinoma: ferroptosis is noteworthy  Frontiers

A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous s...

A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia  Wiley

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular ca...

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma  Nature

Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carc...

Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma  Nature

Hypoxia-induced DTL promotes the proliferation, metastasis, and sorafenib resistance of hepatocel...

Hypoxia-induced DTL promotes the proliferation, metastasis, and sorafenib resistance of hepatocellular carcinoma through ubiquitin-mediated degradation of SLTM and subsequent Notch pathway activation  Nature

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FL...

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial  The Lancet

CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma | Cell D...

CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma | Cell Death & Disease  Nature

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellu...

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression  Nature

Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT ...

Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma  Frontiers

Durvalumab/Tremelimumab Improves Overall Survival vs Sorafenib in Patients With Advanced Hepatoce...

Durvalumab/Tremelimumab Improves Overall Survival vs Sorafenib in Patients With Advanced Hepatocellular Carcinoma HIMALAYA  The ASCO Post

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as ...

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer | Scientific Reports  Nature